David Bowers, Allan House, and David Owens, School of Medicine, University of Leeds, UK
David Bowers, Allan House, and David Owens, School of Medicine, University of Leeds, UK (John Wiley & Sons, West Sussex, 2001), 202 pages, ISBN 0-471-48976-X, 19.99 or $35.00.
This book was written for health care professionals seeking to understand clinical research literature. It is written for clinicians who need to read and interpret clinical papers, clinicians involved in research, people involved in the education and training of clinicians, and students who may one day need to read or write a clinical paper.
The volume is packed with information. This is both a strength and a weakness. On the plus side is all the detail that breaks down scientific terms and analytical tools in such a way that even a novice to the field of clinical trials can understand them. But it is dense. At times it seems like there is too much information, and readers may wonder how they are going to make sense of it all. Dividing the books 30 chapters into seven parts helps to organize the wealth of information.
The first part is designed to help readers learn who wrote a research paper and discover the authors objectives. Succeeding parts include discussions of descriptive, analytic, and intervention studies; the research subjects involved in a study; different types of data; how to interpret a research papers results; how and why different statistical tests are used and what a reader might infer from that information; and, finally, how authors use tables, pictures, and text to inform the reader about what theyve done.
The main weakness, however, is that the authors break their own rules. Although they devote the first chapter of the book to helping readers learn about authors qualifications, nowhere do the authors give us such information about themselves. We know only their names and the university for which they work, nothing else. The lack of a bibliography listing other sources about how to write or understand clinical papers also undermines the works authority. I want to know where this information comes from. And, if it is based solely on the authors experience and expertise, then I want to know what qualifies them as experts.
Having said that, I want to stress that this book is an excellent review of the components of a clinical paper and a worthwhile reference work.
Jeremiah Kerber is the assistant editor of Applied Clinical Trials.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.